Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Co-Diagnostics ( (CODX) ) has issued an announcement.
On July 10, 2025, Co-Diagnostics, Inc. received a notification from the NASDAQ Stock Market granting an additional 180-day grace period until January 5, 2026, to meet the $1.00 minimum bid requirement. The company plans to address this issue, potentially through a reverse stock split, to maintain its NASDAQ listing, which is crucial for its market presence and stakeholder confidence.
The most recent analyst rating on (CODX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Co-Diagnostics stock, see the CODX Stock Forecast page.
Spark’s Take on CODX Stock
According to Spark, TipRanks’ AI Analyst, CODX is a Neutral.
Co-Diagnostics’ overall stock score is primarily impacted by its poor financial performance, reflected in declining revenues and net losses. Despite advancements in product development and strategic partnerships, the company’s financial instability and unattractive valuation hinder its stock potential. Technical indicators show bearish momentum, adding to the negative outlook.
To see Spark’s full report on CODX stock, click here.
More about Co-Diagnostics
Co-Diagnostics, Inc. operates in the biotechnology industry, focusing on molecular diagnostics. The company develops and sells diagnostic tests, primarily targeting infectious diseases, and is known for its innovative testing technologies.
Average Trading Volume: 600,293
Technical Sentiment Signal: Sell
Current Market Cap: $9.5M
See more insights into CODX stock on TipRanks’ Stock Analysis page.